Spironolactone Therapy in Heart Failure

Introduction to Spironolactone Therapy

The European Society of Cardiology recommends spironolactone as a Class I, evidence-based therapy for all patients with symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF) (NYHA Class II-IV, LVEF ≤35-40%) to reduce mortality by 30% and heart failure hospitalizations by 35%, provided potassium is <5.0 mEq/L and creatinine is <2.5 mg/dL 1, 2

Initiate spironolactone in patients with LVEF ≤35-40%, NYHA Class II-IV symptoms, serum potassium <5.0 mEq/L, serum creatinine <2.5 mg/dL, and already on ACE inhibitor/ARB and beta-blocker 1, 2
The American College of Cardiology recommends starting with 12.5-25 mg once daily and titrating to the target dose of 25-50 mg once daily after 4-8 weeks if tolerated and potassium remains <5.0 mEq/L 1, 3

Critical monitoring schedule to prevent life-threatening hyperkalemia: check potassium and creatinine within 3 days of initiation, at 1 week, monthly for 3 months, and every 3 months thereafter 2, 3, 4
For patients intolerant of 25 mg daily, reduce to 25 mg every other day, and the maximum recommended dose is 50 mg daily 1, 3

If potassium is 5.0-5.5 mEq/L, continue current dose with close monitoring; if potassium is >5.5 mEq/L, halve the spironolactone dose and recheck within 3 days; if potassium is >6.0 mEq/L, stop spironolactone immediately 1, 4

For Heart Failure with Mid-Range Ejection Fraction (HFmrEF), spironolactone receives a Class 2b recommendation, particularly for patients with LVEF at the lower end of this spectrum (41-45%) 2, 5
Spironolactone is NOT routinely recommended for Heart Failure with Preserved Ejection Fraction (HFpEF), but may be considered in certain cases, such as LVEF at the lower end (45-50%) or poorly controlled hypertension 6, 2

Hyperkalemia risk increases dramatically when combined with ACE inhibitors/ARBs, and do not combine spironolactone with other potassium-sparing diuretics (amiloride, triamterene) 4, 7
Gynecomastia occurs in approximately 10% of men on spironolactone, and consider switching to eplerenone if this occurs 8, 1

The American College of Cardiology notes that spironolactone is NOT routinely recommended for HFpEF, as the TOPCAT trial showed no significant reduction in the primary composite endpoint of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization (HR 0.89, 95% CI 0.77-1.04, P=0.14) 9
The American College of Cardiology suggests that spironolactone may be considered in HFpEF for patients with LVEF at the lower end of the preserved spectrum (45-50%) where post-hoc analyses suggest potential benefit, poorly controlled hypertension as add-on therapy, or symptomatic patients with elevated BNP or recent HF admission who meet TOPCAT criteria (LVEF ≥45%, eGFR >30 mL/min/1.73m², creatinine <2.5 mg/dL, potassium <5.0 mEq/L) 9
The TOPCAT trial showed that hospitalization for heart failure was reduced (HR 0.83, 95% CI 0.69-0.99), but this benefit was driven entirely by the Americas cohort, with no benefit in Russia-Georgia where medication adherence was questionable 9